AdvertisementSupported byBusiness BriefingBy ReutersKaloBios Pharmaceuticals said on Monday that two directors had resigned after the arrest of Martin Shkreli, who had been its chief executive, on securities fraud charges this month. Tom Fernandez and Marek Biestek resigned from the KaloBios board on Sunday, the company said in a regulatory filing. Both men had worked with Mr. Shkreli, initially at MSMB Capital, the hedge fund he and Mr. Biestek founded. Mr. Fernandez also worked at Retrophin, a drug company Mr. Shkreli led before running Turing Pharmaceuticals. MSMB and Retrophin are at the center of the indictment against Mr. Shkreli, 32, who has pleaded not guilty. Advertisement